Siegfried Holding AG

FDA Approves ILUVIEN Label Expansion for Chronic Non-Infectious Uveitis Treatment

2 months ago

• The FDA has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) to include treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, in addition to its existing diabetic macular edema indication. • ANI Pharmaceuticals plans to begin marketing ILUVIEN under the combined label later this year, enhancing treatment options for patients with these serious ocular conditions. • The company has extended its supply agreement with Siegfried Holding AG through 2029, including upgrades to manufacturing equipment and significant capacity expansion to ensure product availability.